> **WHO** **AMR** **Products** **Data** **Analysis**
>
> <img src="./s5ehaaq4.png" style="width:4.5625in;height:2.5in" />1

**Distributions** **of** **product** **type**

> Non-traditional : 286 (42.8%) Antibiotics : 383 (57.2%)
>
> <img src="./lpj0yexd.png"
> style="width:4.63542in;height:2.59375in" />2
>
> **Distributions** **of** **R&D** **phase**
>
> Phase I :- 310 ( 46.3% ) Phase II :- 186 ( 27.8% ) Phase III :-146 (
> 21.8% ) Preregistration :- 27 ( 4.04% )
>
> <img src="./eifpj0yk.png" style="width:4.32292in;height:4.5in" />3
>
> **Top** **Antibacterial** **Class**
>
> Bacteriophage
>
> <img src="./hz12bprq.png"
> style="width:4.16667in;height:4.15625in" />4
>
> **Top** **Indication**
>
> Gram negative infection
>
> <img src="./ggzgsjgu.png"
> style="width:4.29167in;height:4.0625in" />5
>
> **Top** **developers**
>
> Qpex GSK
